Start of Main Content
Case
Vioxx: Too Risky for Merck?
Author(s)
This case follows Merck's pharmaceutical product, Vioxx, from initial development to launch and subsequent withdrawal, and considers the decisions made at each stage by the Merck executives involved. The case concludes by examining the financial impact of the Vioxx withdrawal on the company and on the Merck stock value.
Date Published:
01/01/2007
Discipline:
Finance;Organizational Behavior
Key Concepts:
Drug development, Drug development risk, Risk in pharmaceutical industry, Investment in drug development, Withdrawal of drugs from the market
Citations:
Petersen, Mitchell A., Rashmi Singhal. Vioxx: Too Risky for Merck?. 5-207-253 (KEL289).
